Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background: An association between combination antiretroviral therapy (cART) and diabetes-related comorbidities (DRCs)
has been found in some countries. However, data on the incidence of DRCs among cART recipients in Botswana are not
available. The objectives of this study were to estimate the incidence of DRCs among cART recipients, assess the time-to-event
in the presence of censored cases and identify cART regimens most associated with DRCs.
Methods: 531 patients who were on cART at Princess Marina Hospital (PMH) HIV clinic and Bontleng HIV clinic were
identified and retrospectively followed for 12 years. Each of the 531 patients was on one of the three standard first-, second- or
third-line cART regimens. Person-years (PY) were used to compute the incidence of DRCs. Kaplan-Meier survival analysis was
performed to compare survival of first-line cART patients to that of second-line/third-line cART patients. Cox regression was
used to investigate associations with DRCs.
Results: The incidence of DRCs was found to be 26.8/1000 PY, with total time of exposure of 3316 PY. The average duration to
event for all the 3 regimens was 11.72�±0.20 years. The first-line cART regimen had a shorter mean �± SE duration of 10.59�±0.26
years to the event compared to 12.69�±0.24 years for the second-line/third-line regimen. Both the first-line cART and secondline/
third-line cART were associated with DRCs but recipients on the first-line cART had a significantly shorter survival than
recipients on second-line/third-line cART (Log-rank X2=8.98, p<0.003).
Conclusion: Both the first-line cART and second-line/third-line cART were associated with DRCs but the risk of developing
DRCs per year of exposure was significantly greater for patients who were on first-line cART compared to those who were on
second-line/third-line cART. Close monitoring of current cART treatment in patients and possible development of DRCs and
other chronic non-communicable diseases is recommended in an effort to improve longevity and quality of life in people living
with HIV/AIDS.
Biography
Jose Gaby Tshikuka Mulumba, Department of Public Health Medicine, Faculty of Medicine, University of Botswana, Botswana. Her research is mainly focused on Epidemiology, public health and Infectious Diseases.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals